{"id":892551,"date":"2025-10-06T09:18:18","date_gmt":"2025-10-06T13:18:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/"},"modified":"2025-10-06T09:18:18","modified_gmt":"2025-10-06T13:18:18","slug":"estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/","title":{"rendered":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements"},"content":{"rendered":"

<\/p>\n

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements<\/b><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE<\/a>)–Estrella Immunopharma, Inc.<\/b><\/a> (NASDAQ: ESLA) (\u201cEstrella\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS\u00ae<\/sup> T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d). This confirmation follows the Company\u2019s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates.<\/p>\n

\nSpecifically, on September 23, 2025, the Company received two letters from the Listing Qualifications Department of Nasdaq. The first letter confirmed the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The second letter confirmed the Company complies with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). Nasdaq has advised that both matters are now closed.<\/p>\n

About Estrella Immunopharma<\/b><\/p>\n

\nEstrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS\u00ae T-cell therapies to treat cancers and autoimmune diseases. Estrella\u2019s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella\u2019s lead product candidate, EB103, utilizes Eureka\u2019s ARTEMIS\u00ae technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka\u2019s ARTEMIS\u00ae technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.<\/p>\n

\nFor more information about Estrella, please visit www.estrellabio.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251006214562\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations
\n
Estrella Immunopharma, Inc.
\n
IR@estrellabio.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (\u201cEstrella\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS\u00ae T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d). This confirmation follows the Company\u2019s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates. Specifically, on September 23, 2025, the Company received two letters from the Listing Qualifications Department of Nasdaq. The first letter confirmed the Company has regained compliance with … <\/p>\n

Continue reading “Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892551","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEstrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (\u201cEstrella\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS\u00ae T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d). This confirmation follows the Company\u2019s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates. Specifically, on September 23, 2025, the Company received two letters from the Listing Qualifications Department of Nasdaq. The first letter confirmed the Company has regained compliance with … Continue reading "Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T13:18:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements\",\"datePublished\":\"2025-10-06T13:18:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"name\":\"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-06T13:18:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk","og_description":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (\u201cEstrella\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS\u00ae T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d). This confirmation follows the Company\u2019s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates. Specifically, on September 23, 2025, the Company received two letters from the Listing Qualifications Department of Nasdaq. The first letter confirmed the Company has regained compliance with … Continue reading \"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-06T13:18:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements","datePublished":"2025-10-06T13:18:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/","name":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-06T13:18:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251006214562r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892551"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}